Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity-Reference-Cited by-同舟云学术

Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity

Published:2024-09-05 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Mochel Jonathan P.,Ward Jessica L.,Blondel Thomas,Kundu Debosmita,Merodio Maria M.,Zemirline Claudine,Guillot Emilie,Giebelhaus Ryland T.,de la Mata Paulina,Iennarella-Servantez Chelsea A.,Blong April,Nam Seo Lin,Harynuk James J.,Suchodolski Jan,Tvarijonaviciute Asta,Cerón José Joaquín,Bourgois-Mochel Agnes,Zannad Faiez,Sattar Naveed,Allenspach Karin

Funder

CEVA Sante Animale

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-71202-y.pdf

Reference126 articles.

1. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The diabetes prevention program outcomes study. Lancet Diabetes Endocrinol. 3(11), 866–875. https://doi.org/10.1016/S2213-8587(15)00291-0 (2015).

2. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed 09 Dec 2023.

3. Birkeland, K. I. et al. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT-2 inhibitors? A large European observational study. Diabetes Obes. Metab. 21(4), 968–974. https://doi.org/10.1111/dom.13612 (2019).

4. Butler, J. et al. EMPEROR-reduced trial committees and investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: The EMPEROR-reduced trial. Eur. Heart J. 42(13), 1203–1212. https://doi.org/10.1093/eurheartj/ehaa1007 (2021).

5. Inzucchi, S. E. et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. Diabetes Obes. Metab. 22(4), 631–639. https://doi.org/10.1111/dom.13938 (2020).